THC degradation does not impair the accuracy of THC doses aerosolized by the metered-dose SyqeAir inhaler: a 24-month stability trial

被引:4
作者
Aviram, Joshua [1 ]
Atzmony, Daniella [1 ]
Frenklakh, Anna [1 ]
Kroll, Asaf [1 ]
Zaks, Ilana [1 ]
Hazekamp, Arno [2 ]
机构
[1] Syqe Med Ltd, 14 Hatchiya St,Studio 211, IL-6816914 Tel Aviv, Israel
[2] Hazekamp Herbal Consulting, Leiden, Netherlands
关键词
Phytocannabinoids; Medical cannabis; Stability; Inhalation; CROSS-SECTIONAL SURVEY; CANNABIS;
D O I
10.1186/s42238-022-00166-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Although the worldwide use of medical cannabis (MC) is on the rise, there is insufficient data regarding the long-term stability of phytocannabinoids in the plant material under different storage conditions. Specifically, there is insufficient data on the effect of storage conditions on the availability of (-)- increment (9)-trans-tetrahydrocannabinol (THC) in vaporized cannabis. The Syqe inhaler delivers metered doses of phytocannabinoids by inhalation and utilizes accurate quantities of ground cannabis inflorescence packaged in tamper-proof cartridges. We aimed to assess the stability of phytocannabinoids in ground cannabis before and after packaging in Syqe cartridges as well as the reproducibility of THC delivery in the aerosolized dose. Methods Ground MC inflorescence was stored under different temperature and humidity conditions, before or after being packaged in Syqe cartridges. Concentrations of the major phytocannabinoids therein were analyzed at different time points using ultra-high performance liquid chromatography (U-HPLC). THC doses aerosolized via the Syqe inhaler were evaluated using cartridges stored for up to 2 years at 25 degrees C. Every vapor chip contains 13.5 +/- 0.9 mg of ground MC powder. Results No significant changes were observed in phytocannabinoid concentrations in ground cannabis inflorescence after 3 months of bulk storage in a polypropylene container and sealed in an aluminum foil pouch at 5 degrees C. In contrast, significant changes in phytocannabinoid concentrations were found when ground inflorescence was stored in the cartridges at 25 degrees C for 2 years. Specifically, CBGA, THCA, and total THC concentrations decreased from 0.097 +/- 0.023, 2.7 +/- 0.3, and 2.80 +/- 0.16 mg/chip at baseline to 0.044 +/- 0.007 (55% decrease), 1.50 +/- 0.27 (44% decrease), and 2.20 +/- 0.083 (21% decrease) mg/chip following 2 years, respectively, while CBN and THC concentrations increased from 0.005 +/- 0.005 and 0.44 +/- 0.11 mg/chip at baseline to 0.14 +/- 0.006 (2700% increase) and 0.88 +/- 0.22 (100% increase) mg/chip following 2 years, respectively. Storage at 30 degrees C revealed a steeper change in phytocannabinoid concentrations within an even shorter period. Despite the significant change of relative cannabinoid composition within the cartridge, the actual THC dose present in the aerosol remained relatively stable throughout this period and within the dosage range of 500mcg +/- 25% required for pharmaceutical-grade inhalers. Conclusions MC powder in Syqe cartridges may be stored at room temperature for at least 2 years after production without affecting the aerosolized THC dose delivered to patients by more than +/- 25%. Future studies should analyze additional phytocannabinoids and terpenes in the cannabis inflorescence and assess the stability of different cannabis cultivars following storage in Syqe cartridges.
引用
收藏
页数:9
相关论文
共 18 条
  • [1] The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial
    Almog, Shlomo
    Aharon-Peretz, Judith
    Vulfsons, Simon
    Ogintz, Miri
    Abalia, Hadas
    Lupo, Tal
    Hayon, Yael
    Eisenberg, Elon
    [J]. EUROPEAN JOURNAL OF PAIN, 2020, 24 (08) : 1505 - 1516
  • [2] Long-term effectiveness and safety of medical cannabis administered through the metered-dose Syqe Inhaler
    Aviram, Joshua
    Atzmony, Daniella
    Eisenberg, Elon
    [J]. PAIN REPORTS, 2022, 7 (03) : E1011
  • [3] Short-Term Medical Cannabis Treatment Regimens Produced Beneficial Effects among Palliative Cancer Patients
    Aviram, Joshua
    Lewitus, Gil M.
    Vysotski, Yelena
    Uribayev, Anton
    Procaccia, Shiri
    Cohen, Idan
    Leibovici, Anca
    Abo-Amna, Mahmud
    Akria, Luiza
    Goncharov, Dmitry
    Mativ, Neomi
    Kauffman, Avia
    Shai, Ayelet
    Hazan, Or
    Bar-Sela, Gil
    Meiri, David
    [J]. PHARMACEUTICALS, 2020, 13 (12) : 1 - 16
  • [4] Medical cannabis treatment for chronic pain: Outcomes and prediction of response
    Aviram, Joshua
    Pud, Dorit
    Gershoni, Tamar
    Schiff-Keren, Bareket
    Ogintz, Miriam
    Vulfsons, Simon
    Yashar, Tamar
    Adahan, Haim-Moshe
    Brill, Silviu
    Amital, Howard
    Goor-Aryeh, Itay
    Robinson, Dror
    Green, Leslie
    Segal, Refael
    Fogelman, Yacov
    Tsvieli, Oren
    Yellin, Ben
    Vysotski, Yelena
    Morag, Ofir
    Tashlykov, Vadim
    Sheinfeld, Roee
    Goor, Ruth
    Meiri, David
    Eisenberg, Elon
    [J]. EUROPEAN JOURNAL OF PAIN, 2021, 25 (02) : 359 - 374
  • [5] A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis
    Berman, Paula
    Futoran, Kate
    Lewitus, Gil M.
    Mukha, Dzmitry
    Benami, Maya
    Shlomi, Tomer
    Meiri, David
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [6] Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain
    Boehnke, Kevin F.
    Litinas, Evangelos
    Clauw, Daniel J.
    [J]. JOURNAL OF PAIN, 2016, 17 (06) : 739 - 744
  • [7] David B-T., 2014, RISE DECLINE CANNABI
  • [8] Eisenberg Elon, 2014, J Pain Palliat Care Pharmacother, V28, P216, DOI 10.3109/15360288.2014.941130
  • [9] The Medicinal Use of Cannabis and Cannabinoids-An International Cross-Sectional Survey on Administration Forms
    Hazekamp, Arno
    Ware, Mark A.
    Muller-Vahl, Kirsten R.
    Abrams, Donald
    Grotenhermen, Franjo
    [J]. JOURNAL OF PSYCHOACTIVE DRUGS, 2013, 45 (03) : 199 - 210
  • [10] Human cannabinoid pharmacokinetics
    Huestis, Marilyn A.
    [J]. CHEMISTRY & BIODIVERSITY, 2007, 4 (08) : 1770 - 1804